Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.

The White House has blamed the Biden administration for failing to advance domestic production or fill the reserve.

According to the US Centers for Disease Control and Prevention, substance use disorder (SUD) affects approximately one in six people in the US.

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be ...

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by the accumulation of scar tissue in the ...

This podcast tackles how pharma can drive better commercial packaging collaborations during the transition from clinical to ...

Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for GPCR ...

Concerns around Ixchiq's safety profile in elderly individuals continue as travel-related chikungunya cases increase in the ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the US EoE market ...

Basilea has acquired the global rights for Venatorx Pharmaceuticals’ ceftibuten-ledaborbactam etzadroxil, an antibiotic being ...

Apertura Gene Therapy has entered several licensing agreements to advance CNS treatments using its TfR1 CapX technology.

Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...